<DOC>
	<DOCNO>NCT00315458</DOCNO>
	<brief_summary>The original objective study assess safety efficacy buprenorphine transdermal system ( BTDS ) ( 5 , 10 , 20 ) comparison placebo transdermal system subject moderate severe osteoarthritis pain . However , study terminate early 35 % plan sample size , therefore primary objective change focus safety evaluation .</brief_summary>
	<brief_title>Buprenorphine Transdermal Patch Subjects With Osteoarthritis Pain Requiring Opioids . Includes 52-Week Safety Extension .</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic 25 year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>clinical evidence osteoarthritis hip , knee , spine joint ≥ 1 year currently adequately treat short act opioids . take ≥ 30 ≤ 80 mg oral morphine morphine equivalent per day ≥ 2 week control osteoarthritis pain . require frequent analgesic therapy chronic condition ( ) , osteoarthritis hip , knee , spine . schedule surgery disease site ( e.g. , major joint replacement surgery ) , major surgery would fall within study period . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
</DOC>